XML 44 R12.htm IDEA: XBRL DOCUMENT v3.19.1
Inventory
3 Months Ended
Mar. 31, 2019
Inventory Disclosure [Abstract]  
Inventory
Inventory
The components of inventory are summarized as follows:
(In millions)
As of
March 31,
2019
 
As of
December 31,
2018
Raw materials
$
199.7

 
$
196.3

Work in process
462.3

 
606.7

Finished goods
108.2

 
133.5

Total inventory
$
770.2

 
$
936.5

 
 
 
 
Balance Sheet Classification:
 
 
 
Inventory
$
770.2

 
$
929.9

Investments and other assets

 
6.6

Total inventory
$
770.2

 
$
936.5


During the three months ended March 31, 2019, we sold hemophilia related inventory to Bioverativ with a cost basis totaling $173.5 million pursuant to the terms of the manufacture and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business.
Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.
Proposed Divestiture of Hillerød, Denmark Manufacturing Operations
In March 2019 we entered into a share purchase agreement with FUJIFILM under which FUJIFILM will acquire all of the outstanding shares of our subsidiary that owns our biologics manufacturing operations in Hillerød, Denmark. Upon closing of the proposed transaction, we expect to receive up to $890.0 million in cash, subject to certain working capital adjustments and other contractual terms. As a result, $27.0 million of work in process inventory was reclassified to assets held for sale in our condensed consolidated balance sheets as of March 31, 2019. Following the closing of the proposed transaction, the final purchase price will be adjusted by an amount equal to the difference between our current estimates of working capital and inventory balances that will be transferred to FUJIFILM and the amounts that are ultimately transferred. In addition, upon closing of the proposed transaction, we expect to separately sell certain raw materials remaining at the Hillerød facility to FUJIFILM at carrying value.
For additional information on the proposed divestiture of our Hillerød, Denmark manufacturing operations, please read Note 3, Divestitures, to these condensed consolidated financial statements.